Articles
News, editorials, patient stories, and more.
This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or a qualified healthcare provider before making any health decisions. Full Disclaimer
FDA Grants Breakthrough Therapy Status to Ianalumab for Sjögren’s Disease
The FDA has granted Breakthrough Therapy designation to ianalumab, a potential targeted treatment for Sjögren’s disease.
Read More — FDA Grants Breakthrough Therapy Status to Ianalumab for Sjögren’s Disease »Scientists Pinpoint a 'Hot Spot' on the NMDA Receptor That Could Unlock Targeted Treatments for 'Brain on Fire' Disease
Researchers at Oregon Health & Science University have used near-atomic imaging to identify a precise cluster of binding sites on the NMDA r...
Read More — Scientists Pinpoint a 'Hot Spot' on the NMDA Receptor That Could Unlock Targeted Treatments for 'Brain on Fire' Disease »The Treatment Gap Nobody Talks About: Levothyroxine Isn't the Whole Story
A major new review confirms what many patients already suspect: levothyroxine manages the symptoms but does nothing to stop the underlying a...
Read More — The Treatment Gap Nobody Talks About: Levothyroxine Isn't the Whole Story »New Treatments Show Promise in Immune Thrombocytopenia
Emerging therapies improve platelet counts in immune thrombocytopenia.
Read More — New Treatments Show Promise in Immune Thrombocytopenia »An Oral Drug Shows Long-Term Promise for a Rare Form of Autoimmune Angioedema
A December 2025 study in the Journal of Allergy and Clinical Immunology found that long-term treatment with deucrictibant, an oral bradykini...
Read More — An Oral Drug Shows Long-Term Promise for a Rare Form of Autoimmune Angioedema »Case Report: Atypical AMAN Strikes During Active Pneumonia, Prompting Urgent IVIG and Full Recovery
A case published in Cureus in November 2025 describes an unusual presentation of acute motor axonal neuropathy (AMAN) occurring simultaneous...
Read More — Case Report: Atypical AMAN Strikes During Active Pneumonia, Prompting Urgent IVIG and Full Recovery »A Rare Antibody Made This Axonal Neuropathy Nearly Untreatable — Until the Right Diagnosis Was Made
A case report from the University of Texas at San Antonio documents a highly treatment-resistant case of AMSAN in which the discovery of an...
Read More — A Rare Antibody Made This Axonal Neuropathy Nearly Untreatable — Until the Right Diagnosis Was Made »It Runs in the Family: New Data on Hashimoto's Genetic Risk
The largest familial risk study of Hashimoto's ever conducted has quantified just how much your relatives share your risk. First-degree rela...
Read More — It Runs in the Family: New Data on Hashimoto's Genetic Risk »Novartis Ianalumab First Drug to Reduce Disease Activity and Patient Burden in Sjögren's Disease Phase III Trials
Novartis announces that ianalumab, a dual-mechanism B-cell depleting antibody, achieved statistically significant reductions in Sjögren's d...
Read More — Novartis Ianalumab First Drug to Reduce Disease Activity and Patient Burden in Sjögren's Disease Phase III Trials »A Hidden Cancer Risk in APS-1: What a New Scoping Review Found About Head and Neck Malignancies
A scoping review of 19 APS-1 patients found that head and neck squamous cell carcinomas develop early, often without classic risk factors, a...
Read More — A Hidden Cancer Risk in APS-1: What a New Scoping Review Found About Head and Neck Malignancies »Antiphospholipid Syndrome Is Getting a Second Look: Emerging Therapies May Go Beyond Lifelong Blood Thinners
A new review in Arthritis & Rheumatology highlights how antiphospholipid syndrome is increasingly being understood as an antibody-mediated d...
Read More — Antiphospholipid Syndrome Is Getting a Second Look: Emerging Therapies May Go Beyond Lifelong Blood Thinners »Selective JAK1 Inhibitor Ivarmacitinib Shows Meaningful Benefit in Active Ankylosing Spondylitis Trial
A peer-reviewed study in Arthritis and Rheumatology found that ivarmacitinib, a selective JAK1 inhibitor, significantly improved symptoms in...
Read More — Selective JAK1 Inhibitor Ivarmacitinib Shows Meaningful Benefit in Active Ankylosing Spondylitis Trial »